BackFirst Tracks Biotherapeutics Overview

First Tracks Biotherapeutics Receivables

First Tracks Biotherapeutics's receivables is $2.9M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$2.87M

Peer trimmed avg / median

Loading

First Tracks Biotherapeutics Receivables History

Loading

First Tracks Biotherapeutics vs. peers: Receivables Comparison

Loading

First Tracks Biotherapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

First Tracks Biotherapeutics (TRAX) FAQ

The latest receivables for TRAX is $2.9M as of September 2026. Investors often review this figure alongside First Tracks Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

A receivables figure of $2.9M for TRAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting TRAX's receivables ($2.9M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack First Tracks Biotherapeutics's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.

Questions & Answers